Surrogate endpoints for overall survival in lung cancer trials: a review

References

• Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and drug administration perspective. J Natl Cancer Inst Monogr. 1996;(20):7–9.
   PubMedGoogle Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Oct 8;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Sep;31(27):3327–3334.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Blumenthal GM, Chen H-Y, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014 Oct;19(10):e5–11.
   PubMed Web of Science ®Google Scholar
• Larkins E, Blumenthal GM, Chen H, et al. FDA Approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res. 2016 Nov 1;22(21):5171–5176.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015 Jul 1;21(11):2436–2439.
   PubMed Web of Science ®Google Scholar
• Buyse M, Molenberghs G, Paoletti X, et al. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom J. 2016 Jan;58(1):104–132.
   PubMed Web of Science ®Google Scholar
• A10-05 - Executive Summary 1.1 - Surrogate endpoints in oncology - A10-05_Executive_Summary_v1-1_Surrogate_endpoints_in_oncology.pdf.
   Google Scholar
• Fleming TR. Surrogate endpoints and FDA’s accelerated approval process. Health Aff (Millwood). 2005 Feb;24(1):67–78.
   PubMed Web of Science ®Google Scholar
• Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of north central cancer treatment group trials. Cancer. 2011 Mar;117(6):1262–1271.
   PubMed Web of Science ®Google Scholar
• Imai H, Mori K, Wakuda K, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med. 2015 Mar;10(1):61–66.
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Mori K, Naito T, et al. Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer. 2014 Jan 14;14:18.
   PubMed Web of Science ®Google Scholar
• Mauguen A, Pignon J-P, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013 Jun;14(7):619–626.
   PubMed Web of Science ®Google Scholar
• Tsujino K, Kawaguchi T, Kubo A, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Aug;4(8):994–1001.
   Google Scholar
• Yoshino R, Imai H, Mori K, et al. Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Mol Clin Oncol. 2014 Sep;2(5):731–736.
   PubMedGoogle Scholar
• Li X, Liu S, Gu H, et al. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol. 2012 Nov;138(11):1963–1969.
   PubMed Web of Science ®Google Scholar
• Hotta K, Fujiwara Y, Matsuo K, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009 Mar;4(3):311–317.
   Google Scholar
• Hotta K, Kiura K, Fujiwara Y, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. Plos One. 2011;6(11):e26646.
   Google Scholar
• Hayashi H, Okamoto I, Morita S, et al. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol /ESMO. 2012 Jun;23(6):1537–1541.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Horita N, Nagai K, et al. Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung carcino. J Thorac Oncol. 2016 Sep;11(9):1574–1585.
   PubMed Web of Science ®Google Scholar
• Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013;3:3.
   Web of Science ®Google Scholar
• Imai H, Takahashi T, Mori K, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma. 2014;61(2):233–240.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S. Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials. Transl Lung Cancer Res. 2013 Feb;2(1):6–13.
   PubMedGoogle Scholar
• Hayashi H, Okamoto I, Taguri M, et al. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer. 2013 May;14(3):261–266.
   PubMed Web of Science ®Google Scholar
• Imai H, Mori K, Ono A, et al. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Med Oncol. 2014 Aug;31(8):88.
   PubMed Web of Science ®Google Scholar
• Sekine I, Tamura T, Kunitoh H, et al. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol /ESMO. 1999 Jun;10(6):731–733.
   PubMed Web of Science ®Google Scholar
• Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006 Sep;7(9):741–746.
   PubMed Web of Science ®Google Scholar
• Mandrekar SJ, Qi Y, Hillman SL, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010 Jan;5(1):3–9.
   Google Scholar
• Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US food and drug administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9):1008–1014.
   PubMed Web of Science ®Google Scholar
• Hotta K, Suzuki E, Di Maio M, et al. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79(1):20–26.
   PubMed Web of Science ®Google Scholar
• Fiteni F, Paillard M-J, Westeel V, et al. Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials. Expert Rev Anticancer Ther. 2017 Feb;17(2):167-173.
   Google Scholar
• Clinical Trial Endpoints for the Approval of Non- Small Cell Lung Cancer Drugs and Biologics -UCM259421.pdf.
   Google Scholar
• Fiteni F, Anota A, Westeel V, et al. Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis. Bull Cancer. 2015 Apr;102(4):360–366.
   PubMed Web of Science ®Google Scholar
• Fiteni F, Westeel V, Pivot X, et al. Endpoints in cancer clinical trials. Vol. 151. J Visc Surg. 2014 Feb;151(1):17-22.
   Google Scholar
• Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Sep;31(27):3342–3350.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol Off J Eur Soc Med Oncol /ESMO. 2013 Jun;24(6):1615–1622.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol Off J Am Soc Clin Oncol. 2013 Aug;31(24):3004–3011.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Gorbunova V, Vikström A, et al. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013 Nov;8(11):1409–1416.
   Google Scholar
• Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213–222.
   PubMed Web of Science ®Google Scholar
• Geater SL, Xu C-R, Zhou C, et al. Symptom and quality of life improvement in LUX-lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in asian patients with EGFR mutation-positive advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015 Jun;10(6):883–889.
   Google Scholar